Clinical study of the effects of ulinastatin and dexmedetomidine on postoperative cognitive dysfunction in patients with heart disease

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17012544

Enrollment

Unknown

Registered

2017-09-01

Start date

2017-08-20

Completion date

Unknown

Last updated

2017-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative cognitive dysfunction

Interventions

normal saline group:normal saline intravenous injection

dexmedetomidine group:infusion at a rate of 0.4µg/kg/h

ulinastatin:infusion at a rate of 20000U/kg/h

dexmedetomidine+ulinastatin group:dexmedetomidine0.4µg/kg/h+ulinastain 20000U/kg/h

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Patients undergoing cardiac surgery during cardiopulmonary bypass; ? Patients aged 30-75 years old; ? Patients with American Society of Anesthesiology status of I-III; ? informed consent was obtained from each patient.

Exclusion criteria

Exclusion criteria: ? Patients with a score of 23 or less on the Mini-Metal State Examination before surgery(MMSE); ? Patients with central nervous system diseases amd brain injury; ? Mental illness or using sedative and antidepressant medication; ? Patients who were hearing or vision impaired; ? Patients who suffered second operation during clinical trial; ? Patients with brain lesions before surgery; ? Patients who refused or was unable to complete the study.

Design outcomes

Primary

Measure	Time frame
cognitive function assessment;Brain functional connectivity;	—

Secondary

Measure	Time frame
Inflammatory cytokines;	—

Countries

China

Contacts

Public ContactWang Liwei

Xuzhou Central Hospital

18952170255@163.com+86 18952170255

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026